Clinical trials: Prostatic Disease
Prostatic Cancer
Cleaning the Biopsy Needle in TRUS Bx
Prostate cancer(PCa) is the second most common cancer diagnosed in men. Clinical suspicion of PCa is mentioned in patients with digital rectal examination findings and elevated serum PSA.
- Trial name
- NCT06836271
- Testing
- Isopropyl Alcohol, Povidine-iodine, formaldehit
- Volunteers
- 200 people
- Sponsor
- Hitit University
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
- Conditions
- ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
- Trial name
- NCT07540572
- Testing
- IDE574, Fulvestrant injection
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Recurrent Prostate Cancer
Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition.
- Trial name
- NCT06070272
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Benign Prostatic Hyperplasia
Laser Enucleation of Prostate (LEP) Versus Transurethral Resection of Prostate (TURP)
Benign prostatic hyperplasia (BPH) refers to the proliferation of smooth muscle and epithelial cells of the prostate gland. The enlarged gland has the potential to result in lower urinary tract symptoms (LUTS) secondary to either…
- Trial name
- NCT03062111
- Testing
- ProTouch Laser Enucleation of Prostate (LEP), Transurethral Resection of Prostate (TURP)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Boston University
Prostate Cancer
Validation Study on the Impact of Decipher® Testing - VANDAAM Study
The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same accuracy in African-American men (AAM) as…
- Trial name
- VANDAAM (NCT02723734)
- Testing
- Decipher® Testing
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer, Kidney Cancer
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
This prospective study will compare pre-post pilot test of surgeon-facing, visual decision support among urologists seeing patients with newly diagnosed localized prostate and kidney cancer.
- Trial name
- NCT06965192
- Testing
- Visual, No intervention
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Bone Metastases, Recurrent Prostate Cancer
Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer
This phase 0 trial studies whole body fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) scan and whole body magnetic resonance imaging (MRI) in finding bone metastases in patients with…
- Conditions
- Bone Metastases, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT00956163
- Testing
- magnetic resonance imaging, fluorine F 18 sodium fluoride, positron emission tomography
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive…
- Trial name
- NCT00428714
- Testing
- enzastaurin
- Where
- 11 sites in United States
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Metastatic Prostate Cancer
Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness and safety of 177Lu-PSMA-0057 in metastatic prostate cancer.
- Trial name
- NCT06050239
- Testing
- 177Lu-PSMA-0057
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Prostate Cancer
I-125 Versus Pd-103 for Medium Risk Prostate Cancer
hypothesis: the shorter half-life of Pd-103 versus I-125, will increase the rate of tumor eradication. A total of 660 patients with AJC clinical stage T1c-T2a prostatic carcinoma (Gleason grade 7 to 9 and/or PSA 10-20 ng/ml) will…
- Trial name
- NCT00486499
- Testing
- I-125 versus Pd-103 radioactive seed insertion
- Where
- 2 sites in United States
- Volunteers
- 660 people
- Sponsor
- VA Puget Sound Health Care System
Prostate Cancer
Fulvestrant in Treating Patients With Advanced Prostate Cancer
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00244998
- Testing
- fulvestrant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Cancer of Prostate
Investigation of Three Biomarkers for the Detection of Prostate Cancer
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies.
- Trial name
- NCT06554587
- Testing
- Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Medtechtomarket Consulting Ltd
Prostate Cancer
Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy
To determine the feasibility of using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen- deprivation therapy with external beam radiation therapy.
- Trial name
- NCT03535987
- Testing
- myocardial PET imaging
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer (Diagnosis)
Prehabilitation to Patients With Prostate Cancer
The goal of this feasibility study is to test a newly developed, multicomponent prehabilitation intervention to patients with prostate cancer, to improve their resilience to treatment side-effects.
- Trial name
- PREPP (NCT07162987)
- Testing
- Prehabilitation
- Where
- 3 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Tivantinib in Treating Patients With Metastatic Prostate Cancer
This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01519414
- Testing
- Laboratory Biomarker Analysis, Tivantinib
- Where
- 20 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate
RATIONALE: Chemoprevention therapy is the use of certain drugs such as flutamide to try to prevent the development of cancer. Flutamide may be effective in the prevention of prostate cancer.
- Trial name
- NCT00006214
- Testing
- flutamide
- Where
- 23 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Economic Evaluation of Robot-assisted Laparoscopic Radical Prostatectomy vs Conventional Laparoscopic Radical Prostatectomy and Open Retropubic Radical Prostatectomy in Prostate Cancer: a Real-life Study Based on the French National Healthcare Data System (SNDS)
This study aims to assess the cost-effectiveness ratio and the clinical benefit (survival, disease recurrence, functional results) of the robot-assisted laparoscopic radical prostatectomy compared with other procedures using…
- Trial name
- ECOREPAR (NCT04587284)
- Where
- France
- Volunteers
- 84,667 people
- Sponsor
- University Hospital, Bordeaux
Metastatic Prostate Adenocarcinoma
Evaluation of PSMA Antagonist Produced by Two Different Methods
Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
- Trial name
- NCT04685811
- Testing
- 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Weill Medical College of Cornell University
Metastatic Prostate Cancer
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Primary Objective: To determine whether changes in uptake of [18F]DCFPyL PET/CT scans at baseline and after 6 weeks of treatment for metastatic castrate resistant prostate cancer, correlates with radiographic progression free…
- Trial name
- NCT03585114
- Testing
- [F-18] DCFPyL, PET/CT imaging
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.